Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
These inhibitory effects of GLP-1 could be mediated by activation of vagal afferents in the distal small intestine or by hormonal effects on the NTS-DMV circuitry (123)
Conclusions and Relevance In this cohort study, most patients with overweight or obesity discontinued GLP-1 RA therapy within 1 year, but those without type 2 diabetes had higher discontinuation rates and lower reinitiation rates
3094, issuing a Transfer Order to centralize lawsuits claiming that the manufacturers of GLP-1 RA weight-loss drugs, such as Ozempic, Wegovy, and Rybelsus, did not adequately warn patients and doctors about the risk of severe gastrointestinal side effects